Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Combined modality treatment with organ preservation in invasive bladder cancer
Authors:ID Čufer, Tanja (Author)
Files:.pdf PDF - Presentation file, download (301,39 KB)
MD5: 4953516643DF64DA99FE8A4852D1F3FC
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Background. The standard treatment for muscle-invasive bladder cancer is stillradical cystectomy. However despite mutilating surgery half of the patients eventually develop metastatic disease and subsequently die of the disease. In view of these problems, a bladder-sparing approach using multi-modality treatment with transurethral resection (TUR), irradiation and chemotherapy has been tested in this disease. So far, the results published byfive groups, showed that the survival rates of patients treated by multi-modality therapy with a bladder sparing approach, based on the response to initial TUR and chemotherapy or chemoradiotherapy, are comparable to cystectomy series, while also offering a 60% to 70% chance of maintaining a functioning bladder. The probability of survival with bladder preserved was found to be around 40% at 5-years. The best predictor of successful multi-modality treatment with bladder preservation seems to be a complete response to initial therapy and a close cystoscopic surveillance is obligatoryto allow for cystectomy at earliest opportunity, if necessary. Conclusions. Multimodality treatment with selective bladder preservation offers a chance for long term cure and survival equal to radical cystectomy inmuscle invasive bladder cancer, while also offering a chance of maintaining a normally functioning bladder. It is expected, that the identification of biological factors with a predictive value for successful chemoradiation will allow for a better selection of patients who could benefit from this treatmentin future.
Publication status:Published
Publication version:Version of Record
Publication date:01.03.2000
Publisher:Slovenian Medical Association - Slovenian Association of Radiology, Nuclear Medicine Society, Slovenian Society far Radiotherapy and Oncology, and Slovenian Cancer Society
Year of publishing:2000
Number of pages:str. 21-25
Numbering:Letn. 34, št. 1
Source:Ljubljana
PID:20.500.12556/DiRROS-17938 New window
UDC:616-006
ISSN on article:1318-2099
COBISS.SI-ID:11319513 New window
Copyright:by Authors
Note:BSDOCID51337;
Publication date in DiRROS:23.01.2024
Views:177
Downloads:42
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Title:Kombinirano zdravljenje raka sečnega mehurja z možnostjo ohranitve organa
Abstract:Izhodišča. Radikalna cistekomija je še vedno standarden način zdravljenja mišičnoinvazivnega raka sečnega mehurja. Kljub hudi invalidnosti se pri polovici bolnikov v letih po posegu pojavijo oddaljeni zasevki, ki so vzrok njihovi smrti. Zaradi tega smo v zadnjih letih pri teh bolnikih preizkusili kombinirano zdravljenje z možnostjo ohranitve sečnega mehurja. Do sedaj objavljeni izsledki petih skupin kažejo, da je preživetje bolnikov zdravljenihz kombinacijo transuretralne resekcije (TUR), kemoterapije in obsevanja ter z ohranitvijo mehurja v primerih doseženega popolnega odgovora na zdravljenje, primerljivo s preživetjem bolnikov zdravljenih s cistekomijo. Ob tem okoli 60 do 70% bolnikov ohrani funkcionalen sečni mehur, petletno preživetje teh bolnikov pa je okoli 40%. Najpomembnejši napovedni dejavnik učinkovitega zdravljenja je popolen odgovor na TUR, kemoterapijo ali kemoradioterapijo. Skrben nadzor bolnikov z rednimi cistoskopskimi pregledi paomogoča takojšnjo rešitveno cistektomijo. Zaključki. Kombinirano zdravljenjeraka sečnega mehurja z ohranitvijo organa omogoča pri določenih bolnikih podobno stopnjo ozdravitve in preživetja kot radikalna cistektomija, ob enem pa omogoča tudi ohranitev sečnega mehurja in njegove funkcije. Pričakujemo, da bo na podlagi bioloških dejavnikov v prihodnosti mogoče v naprej izbrati bolnike z večjo verjetnostjo odgovora na kemoradioterapijo, karbo še izboljšalo rezultate kombiniranega zdravljenja in omogočilo ohranitevsečnega mehurja več bolnikom.


Back